CLX - Educational Analysis * US Equities
Educational Analysis * US Equities

CLX

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerCLX
CategoryEducational primer
Last reviewedNovember 17, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It manufactures and markets a familiar set of consumer and professional brands—Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, Burt’s Bees, and, on the professional side, Purell, CloroxPro, and CloroxHealthcare. Its fiscal 2026 net sales were $6.7 billion, generated by roughly 9,200 employees operating in about 25 countries and selling into approximately 95 markets. In April 2026, Clorox completed the acquisition of GOJO Industries, adding Purell-led health and hygiene exposure and expanding its business-to-business footprint.

A 9.4% net margin suggests the company can price its branded products above pure commodity levels and retain some shelf-level pricing power. That is a modest moat in household products, where scale, distribution relationships, and brand recognition matter. The unusual ROE reading of -1920.6%, however, is not a sign of operating losses—Clorox is profitable—but of a balance-sheet structure in which common equity is deeply negative. High debt, significant treasury-stock balances, accumulated deficit-style accounting, or large goodwill after acquisitions can create that mechanical result. So while the operating margin supports the idea that the brands still earn above their input costs, the extremely negative ROE is a capital-structure signal rather than a competitive-advantage score. Investors treating ROE as a quality check should normalize it or pair it with other return metrics.

Financial posture

At a market cap of $13.3 billion, a share price of $110.17, and a P/E ratio of 19.8, Clorox sits in the middle territory for a low-beta defensive staple. The beta is 0.58, meaning the stock has historically moved a little more than half as much as the broad market in either direction. That fits the household-products profile: demand for bleach, cat litter, trash bags, and salad dressing does not swing wildly with the economic cycle.

The snapshot is currently stretched technically: RSI is 83.1, above typical overbought thresholds, and the stock is trading well above its 50-day exponential moving average of $93.84. Those readings describe price momentum, not a valuation call. Profitability remains intact—net margin 9.4%—but the ROE of -1920.6% again requires context. Because equity is negative, the P/E becomes a cleaner read of what investors are paying for current earnings than any price-to-book or ROE-based metric. Notably, fiscal 2026 diluted EPS fell 26%, so the current multiple is being applied to a lower earnings base than the prior year. That puts modest pressure on the “defensive premium” narrative unless margins and volumes re-expand.

Strategic priorities & outlook

Clorox’s most recent 10-K frames its near-term agenda around the IGNITE strategy. The four stated choices are: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, management is focused on completing and optimizing a new enterprise resource planning system and a broader digital transformation to drive long-term efficiencies in supply chain, digital commerce, innovation, and brand building.

The company also says it will invest in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient company and deliver consistent, profitable growth. Integration of the April 2026 GOJO acquisition and expansion in health and hygiene—especially in professional and institutional markets—is a separate priority. One concrete event worth tracking is the Glad bags and wraps venture with Procter & Gamble, which expired on January 31, 2026. Clorox bought P&G’s 20% interest, and Glad now holds the relevant core intellectual-property licenses on a royalty-free basis, giving Clorox full control but also removing a partner that had helped fund and manage the franchise.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox faces macro exposures that are typical of the category rather than unique to the ticker. Raw materials matter: resins and plastics for Glad and Brita, agricultural inputs for Hidden Valley, paper/pulp-related packaging, and chemicals for cleaning products. Resin and freight costs can move with oil prices, while prolonged inflation can pressure input and logistics spending.

The company also has meaningful customer concentration. Walmart alone accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half. That creates negotiation leverage for retailers and makes promotional pricing, shelf placement, and private-label competition ongoing risks. On the regulatory side, disinfectant claims, chemical ingredients, and environmental rules are part of the industry landscape; any EPA, state-level, or international regulation around chemicals such as PFAS or volatile organic compounds could affect formulations and compliance costs.

Currency and trade policy are relevant as well. With sales in roughly 95 markets and operations in 25 countries, a stronger U.S. dollar could dampen translated overseas revenue and create competitive pressure in markets where input costs are U.S.-dollar denominated. Tariffs or trade disputes affecting packaging, raw materials, or manufacturing equipment would also flow through margins in an industry known for tight cost control.

Recent developments

Recent headlines offer a mix of sentiment and institutional activity rather than operational surprises. On November 13, 2026, 247wallst.com published “A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer,” a general warning that an unusually elevated yield can reflect share-price weakness rather than strength. The piece was not specifically about Clorox, but it fits the broader climate for high-yield consumer names. On November 12, 2026, defenseworld.net noted that Commonwealth Equity Services LLC acquired shares of The Clorox Company, a routine institutional-positioning update that simply shows one advisor adding to or initiating a position.

The market backdrop was constructive: on November 11, 2026, schaeffersresearch.com reported the Nasdaq jumping 464 points on a broad tech rally. That market action is worth remembering because Clorox’s low 0.58 beta means it usually does not move one-for-one with tech-led rallies. On November 9, 2026, fool.com listed Clox in “3 Magnificent High-Yield Dividend Stocks to Buy Near Their 52-Week Lows,” highlighting the defensive-income angle. Again, this is commentary, not a corporate event; it tells you income-focused publications are watching the name.

Earnings behavior & post-earnings drift

Clorox has beaten the market’s real expectation in 6 of the last 8 quarters, a 75% beat rate, with an average earnings surprise of 11.1%. The average five-trading-day move after earnings over that span has been +7.03%, classified as an upward drift. The most recent reporting history shows that beats do not always produce immediate gains, while misses are not always punished.

In the November 2, 2026 quarter, Clorox earned $1.55 versus a $1.07 estimate, a 44.9% positive surprise. The stock rose 4.34% the next session and 17.39% over the next five days. The prior quarter, August 3, 2026, produced a narrow $1.66 versus $1.64 beat (1.2% surprise) yet the stock gained 6.52% the next day and 9.61% over five days. By contrast, the April 30, 2026 quarter saw a $1.64 versus $1.55 beat (5.8% surprise) but the stock sold off 9.67% the next day and finished the five-day window down 4.49%, suggesting guidance or commentary disappointed despite the headline beat. The February 3, 2026 quarter was a miss: actual EPS $1.39 versus estimate $1.43 (-2.8%), yet the stock rose 2.43% the next day and 5.63% over the next five days.

The next scheduled report is after the close on February 2, 2027, with the consensus EPS estimate at $0.984. The historical pattern suggests that when Clorox does surprise, the five-day follow-through has generally been positive, but the day-one reaction can diverge sharply from the headline number because management commentary, gross-margin trajectory, and input-cost outlook often carry more weight than the EPS print itself.

Frequently Asked Questions

Why is Clorox’s ROE reported at -1920.6% if the company is profitable?

Return on equity equals net income divided by shareholders’ equity. Clorox posted a positive 9.4% net margin, so it is operationally profitable. The extreme negative ROE occurs because book equity is deeply negative—likely driven by debt, share buybacks, accumulated deficits, and acquisition-related accounting. In this situation, ROE becomes mechanically distorted and P/E or operating margins are more useful for judging current health.

What are Clorox’s main strategic priorities according to its 10-K?

The company is executing its IGNITE strategy: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and people work, and continuously evolving the product portfolio. Near-term operational focus includes rolling out a new ERP and broader digital transformation, integrating the April 2026 GOJO acquisition, and expanding professional and institutional health and hygiene markets.

How has CLX typically traded after earnings?

Over the last eight quarters, Clorox has beaten EPS estimates 75% of the time with an average surprise of 11.1% and an average five-day post-earnings gain of 7.03%. However, individual reactions vary: the November 2026 quarter surged 17.39% over five days, while the April 2026 quarter fell 9.67% the next day despite a beat.

For a deeper dive into how institutional analysts currently view earnings revisions, margin assumptions, and the GOJO integration path, consider reviewing the full institutional verdict on Clorox rather than relying on headline ratios alone.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 17, 2026
The Clorox Company · Consumer Defensive / Household & Personal Products
$13.3BMarket cap
19.8P/E
9.4%Net margin
-1920.6%ROE
75%Beat rate, last 8Q
11.1%Avg EPS surprise
7.03%Avg 5-day move after earnings
2027-02-02Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-02$1.55$1.07+44.9%+4.34%+17.39%
2026-08-03$1.66$1.64+1.2%+6.52%+9.61%
2026-04-30$1.64$1.55+5.8%-9.67%-4.49%
2026-02-03$1.39$1.43-2.8%+2.43%+5.63%
2025-11-03$0.85$0.818+3.9%--
2025-07-31$2.87$2.2+30.5%--

Previous CLX editions

Beyond the primer

Get the institutional verdict on CLX

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the CLX verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.